ArticleToxins2019
In Vitro and In Vivo Antimalarial Activity of LZ1, a Peptide Derived from Snake Cathelicidin.
Article in Toxins, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- LL-37 selectively targets Plasmodium-infected erythrocytes and exhibits antimalarial activity.PLoS pathogens · 2026Article
- Peptides derived from exocrine secretions of venomous animals used as traditional Chinese "worm" medicines.Zoological research · 2026Review
- Antimicrobial Peptides: A Promising Solution to the Rising Threat of Antibiotic Resistance.Pharmaceutics · 2024Review
- Antimicrobial peptide-based strategies to overcome antimicrobial resistance.Archives of microbiology · 2024Review
- Antiparasitic Evaluation of Aquiluscidin, a Cathelicidin Obtained fromPathogens (Basel, Switzerland) · 2024Article
- The Potential Use of Peptides in the Fight against Chagas Disease and Leishmaniasis.Pharmaceutics · 2024Review
- Design methods for antimicrobial peptides with improved performance.Zoological research · 2023Review
- Aquiluscidin, a Cathelicidin fromMicroorganisms · 2023Article
- Toxins from Animal Venoms as a Potential Source of Antimalarials: A Comprehensive Review.Toxins · 2023Review
- Bioactive Peptides against Human Apicomplexan Parasites.Antibiotics (Basel, Switzerland) · 2022Review
- Released Parasite-Derived Kinases as Novel Targets for Antiparasitic Therapies.Frontiers in cellular and infection microbiology · 2022Review
- A designed antimicrobial peptide with potential ability against methicillin resistantFrontiers in microbiology · 2022Article
- Antimicrobial peptides: mechanism of action, activity and clinical potential.Military Medical Research · 2021Review
- Activity of Anti-Microbial Peptides (AMPs) againstBiomolecules · 2021Review
- Article
- Review
- Antimalarial Agents as Therapeutic Tools Against Toxoplasmosis-A Short Bridge between Two Distant Illnesses.Molecules (Basel, Switzerland) · 2020Review
- Snake Cathelicidin Derived Peptide Inhibits Zika Virus Infection.Frontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimalarial drug resistance is an enormous global threat. Recently, antimicrobial peptides (AMPs) are emerging as a new source of antimalarials. In this study, an AMP LZ1 derived from snake cathelicidin was identified with antimalarial activity. In the in vitro antiplasmodial assay, LZ1 showed strong suppression of blood stage
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.